

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 August 2023 (03.08.2023)



(10) International Publication Number
WO 2023/146983 A1

(51) International Patent Classification:

A61K 31/12 (2006.01) A61K 31/137 (2006.01)
A61K 31/485 (2006.01)

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/011649

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(22) International Filing Date:

26 January 2023 (26.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/303,285 26 January 2022 (26.01.2022) US

(71) Applicant: **AARDVARK THERAPEUTICS, INC.**
[US/US]; 4747 Executive Drive, Suite 1020, San Diego, CA
92121 (US).

(72) Inventors: **LEE, Tien-Li**; 4747 Executive Drive, Suite
1020, San Diego, CA 92121 (US). **ZHENG, Zhenhuan**;
4747 Executive Drive, Suite 1020, San Diego, CA 92121
(US). **TU, Yu-Hsing**; Tulex, 5 Cedarbrook Drive, East
Windsor, NJ 08512 (US).

(74) Agent: **OSTER, Jeffrey**; Aardvark Therapeutics Inc., 4747
Executive Drive, Suite 1020, San Diego, California 92121
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: LIQUID RESIN EXTENDED-RELEASE ORAL NALTREXONE FORMULATION FOR TREATING AUTISM-RELATED DISORDERS

(57) Abstract: There is disclosed a liquid resin extended-release oral naltrexone formulation suspension comprising from, about 1.0 mg/ml to about 10.0 mg/ml naltrexone in a resin, wherein no more than 30% of the total naltrexone dose administered is released within one hour and wherein no more than 60% of the total naltrexone dose administered is released within two hours. Specifically, there is disclosed a method for treating a child with an autism-type disorder with approximately a teaspoon (about 5 ml) of a liquid resin extended-release oral naltrexone formulation suspension comprising from about 1.0 mg/ml to about 10.0 mg/ml naltrexone in a resin, wherein no more than 30% of the total naltrexone dose administered is released within one hour and wherein no more than 60% of the total naltrexone dose administered is released within two hours.



WO 2023/146983 A1